Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of BIBF 1120 for idiopathic pulmonary fibrosis
NL-OMON37909Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Primary endpoint: Long-term safety. Started Sep 2012; status: active, not recruiting.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON37909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37909.